Case Report: Immunotherapy Plus Chemotherapy and Stereotactic Ablative Radiotherapy (ICSABR): a Novel Treatment Combination for Epstein-Barr Virus-associated Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma

Overview

Journal Front Pharmacol

Date 2023 Aug 24

PMID 37614316

Authors

Ruizhen Li

Ke Cheng

Xiaofen Li

Chen Chang

Wanrui Lv

Li Xiaoying

Pei Zhang

Heqi Yang

Dan Cao

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma (EBVa LEL-ICC) is a rare tumor, characterized by a rich tumor immune microenvironment (TIME). While this tumor is reportedly sensitive to immunotherapy, its response has been inconsistent. This decreased sensitivity was associated with reduced TIME abundance. We report the case of a 53-year-old woman with EBVa LEL-ICC having reduced TIME abundance. The patient presented with a liver lesion, which was detected using ultrasound. Initially, the tumor was sensitive to immunotherapy and chemotherapy (IC), but resistance developed after a short interval. Subsequently, stereotactic ablative radiotherapy (SABR) was added to the patient's treatment, which now consisted of ICSABR. Successful tumor shrinkage was achieved with the combination therapy regimen. Thus, surgery and ICSABR are effective adjuncts to the first-line IC therapy in improving the survival rate of patients with EBVa LEL-ICC. The results of this study support multidisciplinary treatment as a viable treatment strategy for EBVa LEL-ICC.

Citing Articles

Lymphoepithelioma-Like Intrahepatic Cholangiocarcinoma Associated with Epstein-Barr Virus and Hepatitis Virus: Case Report and a Literature Review.

Qin H, Xue D, Guo H Cancer Manag Res. 2024; 16:395-402.

PMID: 38707744 PMC: 11067915. DOI: 10.2147/CMAR.S450575.

References

Grimaldi A, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V . Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014; 3:e28780. PMC: 4106166. DOI: 10.4161/onci.28780. View

Zhu Y, Dang Z, Xu H, Yuan Y, Chen Y, Li Z . High PD-L1 level of advanced hepatic lymphoepithelioma-like carcinoma response favorably to lenvatinib plus toripalimab. Cancer Sci. 2022; 113(5):1880-1884. PMC: 9128174. DOI: 10.1111/cas.15339. View

Huang Y, Zhang C, Huang Q, Yeong J, Wang F, Yang X . Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J Hepatol. 2020; 74(4):838-849. DOI: 10.1016/j.jhep.2020.10.037. View

Weichselbaum R, Liang H, Deng L, Fu Y . Radiotherapy and immunotherapy: a beneficial liaison?. Nat Rev Clin Oncol. 2017; 14(6):365-379. DOI: 10.1038/nrclinonc.2016.211. View

Hiniker S, Chen D, Knox S . Abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366(21):2035. DOI: 10.1056/NEJMc1203984. View

Wang J, Ge J, Wang Y, Xiong F, Guo J, Jiang X . EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nat Commun. 2022; 13(1):866. PMC: 8844414. DOI: 10.1038/s41467-022-28479-2. View

Lv W, Cheng K, Li X, Feng L, Li H, Li J . Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer. Front Oncol. 2022; 11:759652. PMC: 8791849. DOI: 10.3389/fonc.2021.759652. View

Xie Z, Liu L, Lin X, Xie X, Gu Y, Liu M . A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. Mod Pathol. 2019; 33(4):626-638. PMC: 7113185. DOI: 10.1038/s41379-019-0391-9. View

Norkus D, Karklelyte A, Engels B, Versmessen H, Griskevicius R, De Ridder M . A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol. 2013; 8:206. PMC: 3846611. DOI: 10.1186/1748-717X-8-206. View

10.

Iezzoni J, Gaffey M, Weiss L . The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol. 1995; 103(3):308-15. DOI: 10.1093/ajcp/103.3.308. View

11.

Golden E, Demaria S, Schiff P, Chachoua A, Formenti S . An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2014; 1(6):365-72. PMC: 3930458. DOI: 10.1158/2326-6066.CIR-13-0115. View

12.

Song H, Srivastava A, Lee J, Kim Y, Kim K, Kang W . Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology. 2010; 139(1):84-92.e2. DOI: 10.1053/j.gastro.2010.04.002. View

13.

Zhao Q, Chen Y, Du S, Yang X, Chen Y, Ji Y . Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther. 2021; 22(3):175-183. PMC: 8043185. DOI: 10.1080/15384047.2020.1834792. View

14.

Conway J, Rawson R, Lo S, Ahmed T, Vergara I, Gide T . Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. J Immunother Cancer. 2022; 10(9). PMC: 9472156. DOI: 10.1136/jitc-2022-004884. View

15.

Jiang L, Wang L, Li P, Zhang X, Chen J, Qiu H . Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. Onco Targets Ther. 2015; 8:1451-7. PMC: 4474388. DOI: 10.2147/OTT.S84234. View

16.

Loblaw A, Cheung P, DAlimonte L, Deabreu A, Mamedov A, Zhang L . Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol. 2013; 107(2):153-8. DOI: 10.1016/j.radonc.2013.03.022. View

17.

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

18.

Hsu H, Chen C, Huang G, Lee P . Clonal Epstein-Barr virus associated cholangiocarcinoma with lymphoepithelioma-like component. Hum Pathol. 1996; 27(8):848-50. DOI: 10.1016/s0046-8177(96)90460-8. View

19.

Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q . Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer. 2020; 8(2). PMC: 7656907. DOI: 10.1136/jitc-2020-001240. View